EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

Bibliographic Details
Main Authors:	Spindler, Karen-Lise G, Pallisgaard, Niels, Lindebjerg, Jan, Frifeldt, Sanne K, Jakobsen, Anders
Format:	Online
Language:	English
Published:	BioMed Central 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073939/

Similar Items

Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
by: Spindler, Karen Lise Garm, et al.
Published: (2015)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
by: Spindler, K G, et al.
Published: (2013)

Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
by: Spindler, K-L G, et al.
Published: (2014)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
by: Skougaard, Kristin, et al.
Published: (2014)

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
by: Hansen, Torben Frøstrup, et al.
Published: (2012)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
by: Folprecht, Gunnar, et al.
Published: (2014)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
by: Carin A. Uyl-de Groot, et al.
Published: (2018-07-01)

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
by: Burtness, Barbara, et al.
Published: (2016)

The Prognostic Value of Haplotypes in the Vascular Endothelial Growth Factor A Gene in Colorectal Cancer
by: Hansen, Torben F., et al.
Published: (2010)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
by: Yazdi, Mohammad Hossein, et al.
Published: (2015)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
by: CHIADINI, ELISA, et al.
Published: (2015)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
by: Kim, Seung Tae, et al.
Published: (2015)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
by: Meyerhardt, Jeffrey A., et al.
Published: (2012)

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
by: Scartozzi, Mario, et al.
Published: (2012)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
by: Giampieri, Riccardo, et al.
Published: (2015)

The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort
by: Hansen, Torben Frøstrup, et al.
Published: (2014)

Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
by: Jehn, C F, et al.
Published: (2012)

Cetuximab in the management of colorectal cancer
by: Lenz, Heinz-Josef
Published: (2007)

Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma
by: Wang, Xi, et al.
Published: (2015)

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan
by: Schou, Jakob V., et al.
Published: (2014)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
by: Eng, Cathy, et al.
Published: (2016)

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
by: Pentheroudakis, George, et al.
Published: (2013)

Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study
by: Feng, Qingyang, et al.
Published: (2016)

Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort
by: Hansen, T F, et al.
Published: (2014)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
by: Mekenkamp, Leonie JM, et al.
Published: (2012)

Irinotecan, Continuous 5-Fluorouracil, and Low dose of Leucovorin (modified FOLFIRI) as First Line of Therapy in Recurrent or Metastatic Colorectal Cancer
by: Lee, Myung-Ah, et al.
Published: (2005)

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
by: Bazarbashi, Shouki, et al.
Published: (2015)

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
by: Segelov, Eva, et al.
Published: (2016)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
by: Scartozzi, M, et al.
Published: (2011)

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
by: Zhang, Lianhai, et al.
Published: (2013)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy †
by: Sihver, Wiebke, et al.
Published: (2014)

Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells
by: FUKUDA, KAZUMASA, et al.
Published: (2011)

Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
by: Genther Williams, Sybil M, et al.
Published: (2015)

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
by: Tsavaris, Nicolas, et al.
Published: (2002)

Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study
by: Teng, Chieh-Lin Jerry, et al.
Published: (2015)

ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer
by: Trumpi, K., et al.
Published: (2015)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
by: Garcia-Alfonso, Pilar, et al.
Published: (2015)

Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen
by: Dedić Plavetić, Natalija, et al.
Published: (2014)

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
by: Li, Minmin, et al.
Published: (2014)

Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
by: Tougeron, D, et al.
Published: (2014)